reason report
orderli transit earli indic end growth
bottom line yesterday vertex announc import senior
leadership chang outlin intend transit
kewalramani md posit presid ceo effect
april time current presid ceo chairman jeffrey
leiden becom execut chairman hold posit
three year term announc someth surpris
although transit method three year period vertex
appear care studi pitfal biopharma leadership
transit set cours success exampl
industri leiden vertex sinc serv ceo
sinc februari year old leiden expect remain
ceo posit sever year yesterday reassur
us engag compani next year
person profession respons
compani import activ initi
investor like concern tempor
associ chang departur earlier year
compani long-standing cfo ian smith even
last year departur prior evp develop jeff
chodakewitz indic leiden plan
leav posit inde board recent provid
increas compens compani perform leiden
presid expans compani cystic fibrosi drug
portfolio medicin like near futur
vertex revenu grown leiden
also led compani invest extern collabor
product acquisit particularli invest treatment rare
diseas base crispr compani stock perform
strongli tenur increas valu four fold
compani april proxi statement board apprais
dr leiden perform lead exemplari result
compens highest level avail compani
compens grant maintain peer-lead salari total
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
vertex three ceo histori notabl found ceo joshua boger led
compani succeed matt emmen turn
succeed jeff leiden two recent ceo came board director
posit prior appoint dr kewalramani appoint first
compani oper execut ramesh kewalramani vertex two
year compani chief medic offic architect compani drug
develop effort last month compani credit rapid execut
compani develop effort tripl combin advanc record time
nda file
prior join vertex spent year mp varieti role mainli
nephrolog develop group role oversaw legendari renal outcom
studi treat red-hf result signific reduct use
erythropoietin patient cardioren diseas previous train nephrologist
mass gener hospit brigham boston graduat bu medic school
train intern medicin mass gener hospit limit contact dr
kewalramani tenur vertex limit exposur investor analyst
tenur appear strong develop experi nephrolog
rel larg indic fort success execut vertex two tripl
combin pivot trial clear experi expertis make
kind strateg capit alloc organiz decis requir ceo success
activ rather clinic develop determin whether vertex anoth
phase growth futur respect remain unproven quantiti vertex
investor appoint unlik alter cautiou view investor
valu vertex non-cf develop program unlik persuad market
upsid vertex futur capit alloc decis
vertex suggest us dr kewalramani built strong relationship insid compani
rel short tenur compani bring posit physician-
scientist profil compani seek search leiden successor
certainli believ profil highest probabl futur success standard
industri ceo prototyp commerci legal financi oper experi lead
execut larg clinic trial necessarili evid prepared complex
leiden continu respons execut chairman reassur investor
convers yesterday compani ceo jeff leiden emphas would
ceo name form substanc april afterward would still
signific role compani on-going activ execut chairman explain
board director request retain respons four activ tenur
execut chairman april four respons busi develop
investor relat govern affair compani new genet therapi research
boston compani employe report dr kewalramani april dr
leiden continu account board four area day-to-
day involv inform offer reassur sinc includ
area activ dr kewalramani direct experi investor
concern expect high
risk departur function
one corollari appoint key execut longer tenur
compani miss new posit may risk leav compani
vertex case believ continu commerci execut import hope
hear stuart arbuckl chief commerci offic stay compani least
next month launch tripl combin major market around world
knowledg inform stuart interest intent would
concern see leav transit senior execut
vertex remain unknown quantiti investor new cfo charli wagner low
profil cso david altschul larg invis outsid compani undoubtedli
compani progress direct group effort departur among visibl
known execut would concern invest commun particularli
recent departur senior leadership team
reason get excit invest vertex base transit
vertex yet anoth larg biopharmaceut compani deal departur
senior leadership end phase industry-lead growth coincident
market perceiv valu compani intern develop portfolio crest larg part
vertex cf compani leiden presid period unpreced valu
creation base franchis question whether anoth franchis even
smaller one compani futur reassur see dr leiden remain
execut chairman posit decis still littl suggest
compani portfolio contain major untap unreal opportun
leadership transit compani alway couch term orderli transit
compani excel shape effect depart execut presid
period consider valu creation often signal tougher time ahead
experi biopharma incom execut rare prepar new role
commonli qualif align compani past challeng issu rather
futur one exampl compani recent challeng legal board
tend appoint lawyer ceo recent difficulti commerci board
appoint commerci execut role unfortun board rare identifi appoint
execut skill experi abil attun compani futur challeng
vertex case challeng leiden kewalramani convinc invest
commun new ceo manag team address compani futur
challeng like similar matur biopharmaceut busi
celgen celg mp mp even gilead mp
existenti challeng capit alloc notabl vertex like
celgen gilead enjoy tremend cash flow futur core
franchis cf negoti price incom ceo rel littl
on-going commerci activ core busi least competit rear ugli
head howev respons invest cash balanc busi
invest sharehold return technolog program product acquir
advanc late stage develop dr leiden came posit substanti
experi field ventur capitalist previous head
major pharmaceut compani compani posit give execut first-hand
experi develop skill capit alloc drug invest length
learn cycl industri long unfortun million dollar paid
consult firm cant substitut experi vertex incom ceo like
recent ceo celgen gilead mostli learn skill job
public eye frequent on-the-job educ expens exercis industri
fierc competit ever newcom manag team take time learn
invest invest invest much invest decis determin
futur return rel matur busi much quarterli result
short term effect cultur workplac initi medium term effect
expens strateg plan effect sell drug work peopl sick
new manag appoint congratul jeff leiden remark track record
strong leadership cours good fortun good judgement right
place right time two biopharma biggest breakthrough adalimumab
ivacaftor/lumacaftor hope successor bring excel capabl
judgement instinct much bigger shoe fill compani
brand
type event
event trial detail
date known
up/down
expect
phase iib dose rang studi patient
nda file cf patient year old
svb leerink llc research compani file
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
svb leerink vertex select balanc sheet cash-flow item
million
total liabil sharehold equiti
chang asset liabil
chang market secur
purchas treasuri stock
chang capit stock net
net chang cash/equival
begin period
end period
 increas work capit
 acquisit licens invest
oper
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo azn
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
